Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

By D. Lamm, B. Blumenstein, J. Crissman, J. Montie, J. Gottesman, B. Lowe, M. Sarosdy, Robert D. Bohl, H. Grossman, T. Beck and 2 more. Journal of Urology, 2000

1,265 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/110fca6b6426e883a15f5ba10ee6b960d6bbf226

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Burger
2. R. Sylvester
3. M. Rouprêt

In Surgery

1. M. Burger
2. M. Rouprêt
3. M. Babjuk
4. B. V. van Rhijn
5. S. Shariat
6. R. Sylvester

Citations in the corpus

• Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. (2009, background): “Fewer than 30% of patients discontinued therapy, representing an acceptable discontinuation rate regarding other BCG maintenance regimens.(18) Even with these weaknesses our tables allow the clinician to individualize the followup schedule and frequency of cystoscopy in individuals based on their sp”
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019, methodology): “Many different maintenance schedules have been used [111].”
• EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. (2017, neutral): “Many different maintenance schedules have been used; it is not possible, however, to determine which BCG maintenance schedule is the most effective [91,100].”
• Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. (2009, background): “BCG but not intravesical chemotherapy additionally reduces the risk of progression in high-risk NMIBC patients [93–96].”
• EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. (2016, result): “With recurrences after >10 yr, our study along with studies from CUETO, SWOG, and FinnBladder show the need for long-term follow-up in NMIBC patients [5,6,16,17].”
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). (2021, methodology): “Many different maintenance schedules have been used, up to a maximum of 27 instillations over 3 yr [126].”